| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8794637 | Ophthalmology Retina | 2018 | 8 Pages |
Abstract
After conversion to ranibizumab in eyes with persistent DME refractory to bevacizumab, significant functional and anatomic improvements were noted. Visual and anatomic outcomes were similar in TREX and monthly treatment protocols.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Justis P. MD, Kevin BS, Rishi P. MD, Amy S. MD, Andrew P. MD, Alex MD, PhD, Jamie L. BSN, Laura Stiegel, Sunil K. MD,